The First Smart Pill: Digital Revolution or Last Gasp?

Area of Science:

• Pharmaceutical Science
• Medical Ethics
• Health Informatics

Background:

• Abilify MyCite, approved in 2017, is the first ingestible sensor technology designed to track medication adherence.
• It was marketed as a solution to patient nonadherence, gaining support from patients and ethicists.
• The development of Abilify MyCite is rooted in the history of Abilify, a successful antipsychotic medication.

Purpose of the Study:

• To critically examine the narrative surrounding Abilify MyCite's development and claims.
• To analyze how knowledge is constructed within biomedical capitalism regarding adherence technology.
• To reevaluate the purported benefits of Abilify MyCite in addressing nonadherence, patient support, and ethical approval.

Main Methods:

• Historical case study analysis of Abilify and its transformation into Abilify MyCite.
• Critical examination of scientific and marketing literature.
• Analysis of claims regarding patient adherence, support, and ethical considerations.

Main Results:

• The history of Abilify demonstrates how an antipsychotic achieved and maintained blockbuster status for over a decade.
• The case of Abilify MyCite illustrates knowledge construction within biomedical capitalism.
• Claims regarding MyCite's impact on nonadherence, patient support, and ethical approval warrant reexamination.

Conclusions:

• The development and marketing of Abilify MyCite highlight the influence of biomedical capitalism on pharmaceutical innovation.
• A critical perspective is necessary to evaluate the true impact and ethical implications of 'smart pill' technologies.
• Further scrutiny is needed to validate claims of improved patient adherence and support associated with Abilify MyCite.